Saturday 7 November 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −65.7%
- Free cash flow
- −114.9%
Quarter to September 2026, against a year earlier
26.54
0.47
+1.80%
Follow STOK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 3 | 3 | 3 |
| (2.37%) | (45.58%) | (61.10%) | (73.62%) | ||
| (2.00%) | (39.94%) | (53.41%) | (63.42%) | ||
ROIC |
(18.98%) | (225.55%) | (264.77%) | (482.02%) | |
Return on Tangible Assets |
(2.74%) | (51.56%) | (72.84%) | (77.54%) | |
Average Days of Receivables |
15.65 | 69.87 | 115.36 | 130.37 | |
Free Cash Flow per Share |
0.76 | (2.34) | (2.74) | (3.16) | |
Free Cash Flow |
44.92 | (147.69) | (180.68) | (215.72) | |
Capital Expenditures |
(0.67) | (0.87) | (2.69) | (5.41) | |
| Other line items | |||||
Cash ROIC |
7.05% | (20.00%) | (28.30%) | (32.11%) | |
Accounts Receivable Turnover |
35.90 | 9.51 | 5.34 | 2.70 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
74.79% | 451.74% | 611.01% | 675.98% | |
Selling, General and Administrative Expense of Revenue |
36.38% | 225.71% | 298.68% | 337.15% | |
Share Based Compensation of Revenue |
17.48% | 106.73% | 135.72% | 143.33% | |
Operating CF/Net income |
(6.62) | 0.86 | 0.86 | 0.86 | |
Depreciation/Fixed assets |
0.20 | 0.21 | (0.03) | 0.01 | |
Capex/Depreciation |
(1.05) | (1.20) | 17.26 | (44.73) | |
Revenue per Share |
3.11 | 0.51 | 0.42 | 0.41 | |
Operating CF per Share |
0.77 | (2.33) | (2.70) | (3.08) | |
Capex per Share |
(0.01) | (0.01) | (0.04) | (0.08) | |
Capex to Sales |
0.00 | 0.03 | 0.10 | 0.19 |
Columns are period end dates · fundamentals updated 5 Nov 2026